Media stories about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 45.6326268239287 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of T2 Biosystems (NASDAQ TTOO) traded down 6.46% during mid-day trading on Friday, hitting $4.20. 260,963 shares of the stock traded hands. The firm’s 50 day moving average price is $4.09 and its 200 day moving average price is $4.11. The firm’s market cap is $129.21 million. T2 Biosystems has a 12-month low of $2.50 and a 12-month high of $8.04.

T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.01). The company had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $0.79 million. T2 Biosystems had a negative net margin of 1,473.71% and a negative return on equity of 178.83%. On average, equities research analysts predict that T2 Biosystems will post ($1.94) EPS for the current fiscal year.

Several analysts recently commented on TTOO shares. Zacks Investment Research lowered shares of T2 Biosystems from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. ValuEngine upgraded shares of T2 Biosystems from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. T2 Biosystems currently has a consensus rating of “Hold” and a consensus price target of $6.75.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.